Category: atherosclerosis

  • Merck turns to cardiovascular pipeline for its post-Keytruda future

    For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come from its cardiovascular disease pipeline. During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy […]